Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
As you might know, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) just kicked off its latest quarterly results with some very strong numbers. Overall results were decent, with revenues of US$14m beating estimates by75%. Statutory losses were subsequently less thanthe analysts had expected, at US$2.44 per share. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Tonix Pharmaceuticals Holding after the latest results.
Taking into account the latest results, the consensus forecast from Tonix Pharmaceuticals Holding's four analysts is for revenues of US$49.7m in 2026. This reflects a major 71% improvement in revenue compared to the last 12 months. Per-share losses are predicted to creep up to US$9.71. Before this latest report, the consensus had been expecting revenues of US$34.2m and US$10.04 per share in losses. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.
See our latest analysis for Tonix Pharmaceuticals Holding
Despite these upgrades,the analysts have not made any major changes to their price target of US$42.40, implying that their latest estimates don't have a long term impact on what they think the stock is worth. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Tonix Pharmaceuticals Holding, with the most bullish analyst valuing it at US$65.00 and the most bearish at US$22.00 per share. With such a wide range in price targets, analysts are almost certainly betting on widely divergent outcomes in the underlying business. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Tonix Pharmaceuticals Holding's growth to accelerate, with the forecast 192% annualised growth to the end of 2026 ranking favourably alongside historical growth of 63% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 23% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Tonix Pharmaceuticals Holding to grow faster than the wider industry.
The Bottom Line
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Happily, they also upgraded their revenue estimates, and are forecasting them to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for Tonix Pharmaceuticals Holding going out to 2028, and you can see them free on our platform here..
Don't forget that there may still be risks. For instance, we've identified 3 warning signs for Tonix Pharmaceuticals Holding (2 are significant) you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.